about
Synthesis and pharmacological evaluation of analgesic 6-substituted 2(3H)-benzothiazolonesNew substrate analogues of human serotonin N-acetyltransferase produce in situ specific and potent inhibitorsRexinoid bexarotene modulates triglyceride but not cholesterol metabolism via gene-specific permissivity of the RXR/LXR heterodimer in the liver.Enantioseparation and thermodynamic study of naphthalene derivatives, new melatoninergic agonists, on coated amylose [tris(S)-1-phenylethylcarbamate] stationary phase. Transposition to preparative scale.Targeting peroxisome proliferator-activated receptors (PPARs): development of modulators.Novel 1,3-dicarbonyl compounds having 2(3H)-benzazolonic heterocycles as PPARgamma agonists.Old and new inhibitors of quinone reductase 2.Design, synthesis and pharmacological evaluation of new series of naphthalenic analogues as melatoninergic (MT1/MT2) and serotoninergic 5-HT2C dual ligands (I).Design, synthesis and pharmacological evaluation of novel naphthalenic derivatives as selective MT(1) melatoninergic ligands.Design and synthesis of 3-phenyltetrahydronaphthalenic derivatives as new selective MT2 melatoninergic ligands. Part II.Synthesis of 3-phenylnaphthalenic derivatives as new selective MT(2) melatoninergic ligands.Exposure to glycol ethers in a population of French men evaluated by measurement of urinary alkoxycarboxylic acids.Design and synthesis of naphthalenic dimers as selective MT1 melatoninergic ligands.Synthesis of nitroindole derivatives with high affinity and selectivity for melatoninergic binding sites MT(3).Dual CD system in capillary electrophoresis for direct separation of the four stereoisomers of agonist and antagonist melatoninergic ligands.Antioxidant activity of benzoxazolinonic and benzothiazolinonic derivatives in the LDL oxidation model.Three-dimensional quantitative structure-activity relationships of cyclo-oxygenase-2 (COX-2) inhibitors: a comparative molecular field analysis.Investigations of new lead structures for the design of novel cyclooxygenase-2 inhibitors.Comparison of 3D structures and AT(1) binding properties of pyrazolidine-3,5-diones and tetrahydropyridazine-3,6-diones with parent antihypertensive drug irbesartan.Enantiomeric resolution of new aromatase inhibitors by liquid chromatography on cellulose chiral stationary phases.Antioxidant activity of melatonin and a pinoline derivative on linoleate model system.Preparative HPLC separation of methoxytetralins, ligands for melatonin receptors, containing two chiral centers with polysaccharide chiral stationary phases. Determination of enantiomeric purity.Increased susceptibility of low-density lipoprotein to ex vivo oxidation in mice transgenic for human apolipoprotein B treated with 1 melatonin-related compound is not associated with atherosclerosis progression.Design and synthesis of benzofuranic derivatives as new ligands at the melatonin-binding site MT3.Homology modeling of MT1 and MT2 receptors.Lipid-lowering properties of 6-benzoyl-2(3H)-benzothiazolone and structurally related compounds.Synthesis and biological evaluation of new naphtho- and quinolinocyclopentane derivatives as potent melatoninergic (MT1/MT2) and serotoninergic (5-HT2C) dual ligands.Bitopic fluorescent antagonists of the A2A adenosine receptor based on pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine functionalized congeners.Design, synthesis and evaluation of 2-aryl benzoxazoles as promising hit for the A2A receptor.New quinolinic derivatives as melatonergic ligands: Synthesis and pharmacological evaluation.Melatonergic ligands: Design, synthesis and pharmacological evaluation of novel series of naphthofuranic derivatives.Synthesis and pharmacological evaluation of dual ligands for melatonin (MT1/MT2) and serotonin 5-HT2C receptor subtypes (II).New melatonin (MT1/MT2) ligands: design and synthesis of (8,9-dihydro-7H-furo[3,2-f]chromen-1-yl) derivatives.Synthesis and pharmacological evaluation of a series of the agomelatine analogues as melatonin MT1 /MT2 agonist and 5-HT2C antagonist.Novel conformationally constrained analogues of agomelatine as new melatoninergic ligands.Preparation and pharmacological evaluation of a novel series of 2-(phenylthio)benzo[b]thiophenes as selective MT2 receptor ligands.Antagonists of the adenosine A2A receptor based on a 2-arylbenzoxazole scaffold: Investigation of the C5- and C7-positions to enhance affinity.Design of experiments for enantiomeric separation in supercritical fluid chromatography.Synthesis and evaluation of benzoxazolinonic imidazoles and derivatives as non-steroidal aromatase inhibitors.Quantitative structure-activity relationships studies of antioxidant hexahydropyridoindoles and flavonoid derivatives.
P50
Q28191972-4067AD19-3496-459E-B443-DFA701818CF9Q28238260-2EC13F61-C1DC-49D4-87C1-1F20BB66F5C1Q33670343-1AAAC10A-46EC-4192-B18A-92A17420E061Q35290553-55A50F86-6572-45F0-A167-2B87364C858AQ37977108-AFA7EBAD-F7DC-4517-8088-36BCD67BC70DQ38310949-BC21DA24-3744-4C71-A02E-4BF389BC9F12Q38344777-7315AFF6-D8AD-4757-B9B5-1A58E0EB6F59Q39402443-65F1E051-6F24-4C96-90A9-FB2315B0AC63Q39707347-B2571A6B-FE52-46C2-99CA-70668EEA7E76Q39867093-8C9DCC53-5E12-4824-876C-051BAF260A5FQ39941955-C44FC23C-D02F-49BC-8953-55499D907A04Q40507945-18BED988-A185-41AC-BE5B-BB7B0E00A490Q40662858-22C2AF66-FC41-4A62-8B98-6896F680DD0FQ40737354-05CB1632-19F5-4ECE-A268-1148D1188D49Q43084385-1A72B4CE-2C55-4560-81F4-236FC343452BQ43264093-542B727D-B72E-4402-961F-75FFEA043128Q43742626-77F5F051-10FC-4B37-8D9B-92E175F28649Q44120494-3A30F6D2-58CC-413C-9815-7815F7655EE8Q44165973-124E04A1-B6B6-4694-B982-FCC4EAC9C03EQ46441715-5570761F-602D-4D38-9248-7081E6968E04Q46566149-6C011CA4-33E4-4543-B023-82696BD19A05Q46580259-440E3295-7570-4508-8126-C2940942170FQ46664242-32116708-C85B-42E7-9400-21E112201CB3Q46677514-5CAB340B-2186-49AA-9963-62E3D79183A7Q46768093-32F371C6-DFA3-4EBA-AAC1-944A6E8BAABEQ46891599-242DA365-5B68-4323-9135-53D07EE3DFC0Q47442061-09D1F311-F298-4765-AABC-F0A39DDCC3E9Q47751959-9B5EBF80-C886-473C-95CE-9EB1E668E675Q50917169-D63637C3-8462-48EB-BF0E-63DAF4775DC7Q51734608-A5F4792F-B902-45FC-8D7E-4CDFB72DED22Q51739330-0B288CD3-3BDF-4F53-B0E5-5DBFA0221271Q51745295-0CB87A29-2BBE-4769-B977-EB2AD7BC1D19Q51750511-BD16621B-514A-4270-9593-46250CD553C3Q51751895-0D5A324C-FCA6-4875-8378-FD12A07D9356Q51755563-3EC17BB3-BA88-47A5-B0B4-0004F90549BAQ51769168-2CD466F6-FBC4-4B58-A074-03F66550D036Q52740395-950B2BBE-6A5F-4910-81AF-4ABA711F8D91Q53213262-E58BE772-FCF9-43D0-B585-3C5F8197D869Q53633839-78850D45-B535-4057-8177-BF565BF474EBQ53763182-1335EB77-6900-4CE8-9402-4DD71D39C607
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Saïd Yous
@ast
Saïd Yous
@en
Saïd Yous
@es
Saïd Yous
@nl
Saïd Yous
@sl
type
label
Saïd Yous
@ast
Saïd Yous
@en
Saïd Yous
@es
Saïd Yous
@nl
Saïd Yous
@sl
prefLabel
Saïd Yous
@ast
Saïd Yous
@en
Saïd Yous
@es
Saïd Yous
@nl
Saïd Yous
@sl
P214
P106
P1153
7004931697
P213
0000 0001 3968 7557
P214
P31
P496
0000-0001-9221-6535
P7859
viaf-194046302